Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:https://doi.org/10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16. doi:https://doi.org/10.3390/jcm6020016.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180. doi:https://doi.org/10.1002/ajh.21616.
   PubMed Web of Science ®Google Scholar
• Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–89. doi:https://doi.org/10.1111/j.1600-0609.2009.01247.x.
   PubMed Web of Science ®Google Scholar
• Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30. doi:https://doi.org/10.1159/000492187.
   PubMedGoogle Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:https://doi.org/10.1182/bloodadvances.2019000812.
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207. doi:https://doi.org/10.1002/ajh.26036.
   PubMed Web of Science ®Google Scholar
• McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150–154. doi:https://doi.org/10.1002/ajh.20992.
   PubMed Web of Science ®Google Scholar
• Bussel J, Ghanima W, Cooper N, et al. Higher symptom burden in patients with immune thrombocytopenia experiencing fatigue: results from the ITP World Impact Survey (I-WISh). Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; 2020. Abstract 2668. Available from: https://ash.confex.com/ash/2020/webprogram/Paper136546.html.
   Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:https://doi.org/10.1182/bloodadvances.2019000966.
   PubMed Web of Science ®Google Scholar
• German Society of Hematology and Medical Oncology. Onkopedia Leitlinie Immunthrombozytopenie (ITP). October 2020. [cited 2021 Aug 19]. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/immunthrombozytopenie-itp/@@guideline/html/index.html.
   Google Scholar
• Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American Group on Hemostasis and Thrombosis. Blood. 1984;64(6):1179–1183.
   PubMed Web of Science ®Google Scholar
• Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;1(24):2295–2301. doi:https://doi.org/10.1182/bloodadvances.2017009860.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Tavlesse (fostamatinib) summary of product characteristics; 2020. [cited 2021 Aug 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/tavlesse-epar-product-information_en.pdf.
   Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735. doi:https://doi.org/10.1177/2040620719841735.
   Web of Science ®Google Scholar
• Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185(3):503–513. doi:https://doi.org/10.1111/bjh.15803.
   PubMed Web of Science ®Google Scholar
• Tripathi AK, Shukla A, Mishra S, et al. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. Int J Hematol. 2014;99(4):413–417. doi:https://doi.org/10.1007/s12185-014-1533-y.
   PubMed Web of Science ®Google Scholar
• González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol. 2017;106(4):508–516. doi:https://doi.org/10.1007/s12185-017-2275-4.
   PubMed Web of Science ®Google Scholar
• Bussel J, Tkacz J, Manjelievskaia J, et al. Long-term overuse of corticosteroids in patients with immune thrombocytopenia: a real-world analysis of a US claims database. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; 2020. Abstract 849. Available from: https://ash.confex.com/ash/2020/webprogram/Paper133757.html.
   Google Scholar
• Platzbecker U, Heßling J, Hurtz H-J, et al. Retrospective analysis of the disease management of patients with immune thrombocytopenia. Oncol Res Treat. 2017;40(Suppl 3):90. doi:https://doi.org/10.1159/000479566.
   Google Scholar
• Kubasch AS, Kisro J, Heßling J, et al. Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany. Ann Hematol. 2020;99(9):2085–2093. doi:https://doi.org/10.1007/s00277-020-04173-5.
   PubMed Web of Science ®Google Scholar
• Richter H, Dombrowski S, Hamer H, et al. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci. 2015;13:Doc14. doi:https://doi.org/10.3205/000218.
   PubMedGoogle Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008. doi:https://doi.org/10.1056/NEJMra010501.
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Pavlaki AN, Alexandra M, et al. Glucocorticoid therapy and adrenal suppression; 2018. [cited 2021 Aug 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279156/.
   Google Scholar
• Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost. 2015;41(4):395–404. doi:https://doi.org/10.1055/s-0034-1544001.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Greenwood R, Pell J, et al. A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. Blood. 2020;136(Suppl 2):LBA–2. doi:https://doi.org/10.1182/blood-2020-143563.
   Google Scholar
• Pell J, Greenwood R, Ingram J, et al. Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open. 2018;8(10):e024427. doi:https://doi.org/10.1136/bmjopen-2018-024427.
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gao SK, Miller KL, et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcome. 2008;6:13. doi:https://doi.org/10.1186/1477-7525-6-13.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–1432. doi:https://doi.org/10.1016/j.clinthera.2011.09.009.
   PubMed Web of Science ®Google Scholar
• Michel M, te Boekhorst PA, Janssens A, et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology. 2011;16(5):274–277. doi:https://doi.org/10.1179/102453311x13025568942005.
   PubMed Web of Science ®Google Scholar
• Khelif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol. 2019;94(2):200–208. doi:https://doi.org/10.1002/ajh.25348.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–2171. doi:https://doi.org/10.1182/blood-2008-04-150078.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi:https://doi.org/10.1016/S0140-6736(08)60203-2.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–423. doi:https://doi.org/10.1111/bjh.12260.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. doi:https://doi.org/10.1182/blood-2017-04-748707.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Revolade (eltrombopag) summary of product characteristics; 2018. [cited 2021 Aug 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Nplate (romiplostim) summary of product characteristics; 2021. [cited 2021 Aug 19]. Available from: https://ec.europa.eu/health/documents/community-register/2021/20210122150420/anx_150420_en.pdf.
   Google Scholar